Immuno-Biological Laboratories Co.,Ltd. [4570.T]
TOKYO, Jun 15 (Pulse News Wire) – Immuno-biological Laboratories CO.,LTD. (4570.T) reported progress on its development of anti-HIV antibodies in collaboration with Kumamoto University, National Institutes of Biomedical Innovation, Health and Nutrition, and CURED.
Under support from AMED, CURED is conducting GLP-compliant non-clinical toxicity tests involving four-week repeated dosing and recovery trials in monkeys, which are proceeding smoothly without issues. The company plans to initiate master cell bank construction in the current fiscal year and commence clinical trial drug manufacturing in the next fiscal year, followed by submission of a clinical trial application to PMDA.
Any significant developments impacting the group's performance in the March 2027 fiscal year will be disclosed promptly. AMED, or the Japan Agency for Medical Research and Development, supports medical research and was established in 2015.
A master cell bank (MCB) serves as a repository for standardized cells used in regenerative medicine and biopharmaceutical production, ensuring quality control through extensive testing and storage.
🟢 Confidence: High AI-translated content.